Ajanta Pharma Ltd

Ajanta Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ajanta Pharma Ltd

₹ 2,968 -1.94%
03 Dec - close price
ajantapharma.com BSE: 532331 NSE: AJANTPHARM
About

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Key Points

India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]

Website BSE NSE
  • Market Cap ₹ 37,046 Cr.
  • Current Price ₹ 2,968
  • High / Low ₹ 3,486 / 1,850
  • Stock P/E 42.3
  • Book Value ₹ 294
  • Dividend Yield 1.21 %
  • ROCE 31.6 %
  • ROE 23.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 35.2%

Cons

  • Stock is trading at 10.1 times its book value
  • Promoter holding has decreased over last 3 years: -4.08%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of Nifty LargeMidcap 250 BSE 500 Nifty Total Market BSE 400 MidSmallCap Index Nifty MidSmallcap 400

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
885 838 870 951 938 972 882 1,021 1,028 1,105 1,054 1,145 1,187
622 598 664 729 742 802 732 750 738 791 776 815 875
Operating Profit 263 240 207 222 196 170 149 271 291 314 278 330 311
OPM % 30% 29% 24% 23% 21% 17% 17% 27% 28% 28% 26% 29% 26%
30 24 29 33 40 35 37 32 21 14 36 26 19
Interest 0 1 7 1 1 3 1 1 2 2 2 1 6
Depreciation 32 32 31 32 33 33 33 33 34 34 34 34 34
Profit before tax 260 231 198 222 203 168 152 269 276 291 278 322 290
Tax % 25% 17% 24% 21% 23% 20% 20% 23% 29% 28% 27% 24% 25%
196 192 151 175 157 135 122 208 195 210 203 246 216
EPS in Rs 15.10 14.78 11.80 13.63 12.22 10.50 9.54 16.53 15.51 16.68 16.10 19.68 17.33
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
931 1,208 1,474 1,749 1,983 2,126 2,055 2,588 2,890 3,341 3,743 4,209 4,491
706 840 968 1,155 1,292 1,467 1,489 1,904 1,889 2,408 2,934 3,037 3,257
Operating Profit 224 369 505 594 691 658 567 683 1,001 933 808 1,172 1,234
OPM % 24% 31% 34% 34% 35% 31% 28% 26% 35% 28% 22% 28% 27%
6 14 8 14 20 24 21 88 24 112 74 85 95
Interest 19 9 6 5 1 0 1 12 8 10 6 7 11
Depreciation 34 44 52 44 61 60 72 96 116 125 131 135 137
Profit before tax 177 330 456 559 648 623 514 664 900 909 745 1,114 1,181
Tax % 37% 29% 32% 26% 22% 25% 25% 30% 27% 22% 21% 27%
112 234 310 416 507 469 387 468 654 713 588 816 875
EPS in Rs 8.49 17.75 23.47 31.49 38.40 35.50 29.56 35.73 50.38 55.63 45.89 64.82 69.79
Dividend Payout % 13% 15% 17% 17% 23% 0% 20% 24% 13% 11% 15% 79%
Compounded Sales Growth
10 Years: 13%
5 Years: 15%
3 Years: 13%
TTM: 15%
Compounded Profit Growth
10 Years: 13%
5 Years: 16%
3 Years: 7%
TTM: 33%
Stock Price CAGR
10 Years: 16%
5 Years: 35%
3 Years: 28%
1 Year: 51%
Return on Equity
10 Years: 24%
5 Years: 21%
3 Years: 21%
Last Year: 23%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 12 18 18 18 18 18 18 18 17 17 25 25 25
Reserves 382 576 823 1,173 1,550 2,024 2,228 2,581 2,978 3,247 3,363 3,542 3,652
125 130 72 81 1 2 36 75 31 25 36 35 33
200 226 233 207 254 383 383 619 702 711 1,159 927 1,081
Total Liabilities 718 949 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,790
273 279 288 451 589 1,053 1,178 1,472 1,541 1,512 1,496 1,479 1,451
CWIP 12 94 170 240 339 61 262 132 108 153 209 256 349
Investments 8 63 60 86 182 190 78 79 176 147 535 349 702
425 513 629 703 713 1,122 1,147 1,610 1,904 2,188 2,341 2,446 2,289
Total Assets 718 949 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,790

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
234 212 279 326 609 281 375 457 576 562 792 785
-104 -188 -158 -209 -383 -256 -223 -224 -282 -74 -560 65
-104 -20 -105 -117 -202 -0 -147 -129 -318 -460 -108 -1,051
Net Cash Flow 26 4 16 -0 24 25 4 104 -24 28 124 -201

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 59 61 64 78 59 79 82 109 93 111 103 108
Inventory Days 178 164 159 180 186 315 415 276 434 347 283 283
Days Payable 159 132 109 128 157 224 214 202 212 143 147 159
Cash Conversion Cycle 78 94 114 130 88 170 282 184 315 315 240 233
Working Capital Days 59 57 61 90 65 103 119 116 127 141 84 120
ROCE % 39% 55% 57% 52% 46% 34% 24% 27% 32% 29% 23% 32%

Shareholding Pattern

Numbers in percentages

5 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
70.34% 70.48% 70.48% 70.48% 66.11% 66.11% 66.22% 66.22% 66.22% 66.22% 66.27% 66.26%
8.95% 8.64% 8.30% 8.23% 10.07% 10.00% 10.19% 9.99% 9.11% 8.54% 8.36% 9.11%
12.14% 12.29% 12.46% 12.68% 15.37% 15.52% 15.36% 15.60% 16.67% 17.48% 17.41% 17.09%
0.45% 0.45% 0.45% 0.45% 0.45% 0.45% 0.46% 0.00% 0.00% 0.00% 0.01% 0.01%
8.12% 8.14% 8.31% 8.15% 8.00% 7.91% 7.78% 8.21% 8.00% 7.76% 7.94% 7.51%
No. of Shareholders 57,89760,75964,44562,04859,79883,54954,87456,27754,35155,48870,31664,315

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls